Merck MRK announced a definitive agreement to acquire Verona Pharma VRNA for approximately $10 billion. The deal will add ...

Merck & Co.’s ambition to get the first oral PCSK9 inhibitor to market came one step closer this morning as the pharma unveiled a pair of phase 3 wins for enlicitide decanoate in patients with ...

Injectable antibodies targeting PCSK9 have failed to take off as expected in the cholesterol-lowering market, but Merck & Co hopes to do much better with an oral alternative. MK-0616 has been ...

“We want to democratize the PCSK9 pathway, because that is the most potent way to lower LDL cholesterol,” Merck Research Laboratories President Dean Li said at an investor conference in late May.

RAHWAY, N.J., June 09, 2025--Merck Announces Positive Topline Results from Phase 3 CORALreef Trials Evaluating Enlicitide Decanoate for the Treatment of Adults with Hyperlipidemia ...

In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant and clinically meaningful cuts in low ...

Merck announces positive topline results from the first two phase 3 CORALreef trials evaluating enlicitide decanoate for the treatment of adults with hyperlipidemia. News release. Merck. June 9, 2025.

Merck’s pipeline includes Phase 3 PCSK9 inhibitor and GLP-1/glucagon receptor agonist. From tariffs to inflation, macro risks are rising—Matt Maley reveals how he’s trading it all, ...

In this analysis, we explore the potential upside for Merck despite its short-term hurdles. Newsletters Games Share a News Tip. Featured. Featured. ... is intended to be the first oral PCSK9 ...

Enlicitide, a novel macrocyclic peptide, has the potential to be the first approved oral PCSK9 inhibitor. Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced ...